Oral Papillomatosis

Oral papillomatosis is a benign, proliferative disease of the oral mucosa and, less commonly, the skin and other mucosal surfaces, caused by infection with host-specific papillomaviruses. In dogs, the condition is typically caused by canine oral papillomavirus (COPV), a member of the Papillomaviridae family. The disease is characterized by the development of multiple, cauliflower-like, verrucous growths (papillomas) on the lips, tongue, gingiva, palate, and pharynx. These lesions are usually self-limiting, with spontaneous regression occurring within 1 to 5 months as the host mounts an effective cell-mediated immune response. However, in immunocompromised animals, lesions may persist, enlarge, and occasionally undergo malignant transformation to squamous cell carcinoma. Oral papillomatosis is most commonly seen in young dogs (less than 2 years of age), but can occur in any age group, especially in immunosuppressed individuals. The disease is transmitted by direct contact with infected animals or fomites, and the virus enters through microabrasions in the oral mucosa. The incubation period is typically 1 to 2 months. While the condition is generally benign, it can cause significant morbidity due to interference with eating, swallowing, and breathing, particularly when lesions are extensive or located in the pharynx. In rare cases, papillomas may become infected, ulcerated, or hemorrhagic. Diagnosis is usually based on clinical appearance and confirmed by histopathology or molecular techniques such as PCR. Treatment is often unnecessary, but surgical excision, cryotherapy, laser ablation, or immunomodulatory therapy (e.g., azithromycin, imiquimod) may be considered for persistent or obstructive lesions. Prognosis is excellent for immunocompetent animals, with complete regression expected. Prevention relies on minimizing exposure to infected animals and maintaining good hygiene.

The primary etiological agent of oral papillomatosis is the canine oral papillomavirus (COPV), also known as canine papillomavirus type 1 (CPV1). This virus belongs to the genus Lambdapapillomavirus within the family Papillomaviridae. COPV is a non-enveloped, double-stranded DNA virus with an icosahedral capsid. The viral genome is approximately 8,000 base pairs and encodes early (E1, E2, E4, E6, E7) and late (L1, L2) proteins. The E6 and E7 proteins are oncoproteins that interfere with cell cycle regulation, promoting cellular proliferation. The virus is highly species-specific and does not infect humans or other animals. Transmission occurs through direct contact with infected animals, typically via saliva, or through contaminated objects such as food bowls, toys, and bedding. The virus enters the basal layer of the oral epithelium through microabrasions or wounds. The incubation period ranges from 1 to 2 months. The virus replicates in the differentiating keratinocytes of the stratum spinosum and granulosum, leading to the characteristic hyperplastic and papillary growth. The host immune response, particularly cell-mediated immunity, is crucial for viral clearance and lesion regression. Immunosuppression, whether due to age (young animals), concurrent disease, or iatrogenic causes (e.g., corticosteroid therapy), can lead to persistent or severe infections. Other papillomavirus types have been identified in dogs (e.g., CPV2, CPV3, CPV4), but they are less commonly associated with oral lesions. In cats, oral papillomatosis is rare and may be caused by feline papillomaviruses, but the disease is not as well characterized.

Oral papillomatosis is primarily a disease of young dogs, with the highest incidence in animals under 2 years of age. This age predilection is attributed to the immaturity of the immune system, which allows the virus to establish infection and proliferate. The disease is more commonly reported in kennels, shelters, and multi-dog households, where close contact and shared fomites facilitate transmission. There is no known breed or sex predisposition, although some studies suggest a higher incidence in certain breeds, possibly due to genetic factors affecting immune response. The disease is worldwide in distribution, with no geographic or seasonal variation. The prevalence is difficult to estimate because many cases are subclinical or spontaneously resolve without veterinary attention. In a study of canine oral papillomatosis, the median age of affected dogs was 6 months, with a range of 2 months to 2 years. Immunocompromised dogs, such as those receiving chemotherapy or long-term glucocorticoids, are at increased risk for persistent and severe disease. In cats, oral papillomatosis is extremely rare, and the epidemiology is poorly defined. The disease is not zoonotic, and there is no risk of transmission to humans.

The pathophysiology of oral papillomatosis begins with the inoculation of COPV into the basal layer of the oral epithelium through microtrauma. The virus binds to cell surface receptors, likely integrins, and enters the cell via endocytosis. The viral genome is transported to the nucleus, where it establishes itself as an episome. The early genes E1 and E2 are essential for viral DNA replication and maintenance. E6 and E7 proteins bind to and inactivate tumor suppressor proteins, such as p53 and retinoblastoma protein (pRb), respectively, leading to uncontrolled cell proliferation and inhibition of apoptosis. This results in hyperplasia of the stratum spinosum and the formation of papillary projections. The virus replicates in the differentiating keratinocytes of the upper epithelial layers, where the late genes L1 and L2 encode capsid proteins. The assembly of new virions occurs in the nucleus, and the virus is shed from the surface of the lesion. The host immune response, particularly T-cell-mediated immunity, is critical for regression. The lesions typically regress spontaneously as the immune system recognizes viral antigens and mounts a cytotoxic T-cell response. This is evidenced by the infiltration of CD4+ and CD8+ T lymphocytes into the lesions during regression. In immunocompromised animals, the immune response is inadequate, leading to persistent lesions. In rare cases, chronic infection can lead to malignant transformation, particularly in the presence of co-carcinogens such as UV radiation or chronic inflammation. The oncogenic potential of COPV is low, but transformation to squamous cell carcinoma has been reported, especially in older dogs with persistent lesions.

Several factors predispose animals to oral papillomatosis. The most significant is age, with young dogs (less than 2 years) being highly susceptible due to an immature immune system. Immunosuppression, whether from concurrent viral infections (e.g., canine distemper virus), chronic disease, or iatrogenic causes (e.g., corticosteroid therapy, chemotherapy), increases the risk of infection and persistence. Stress, poor nutrition, and overcrowding in kennels or shelters can also compromise immune function and facilitate transmission. Genetic factors may play a role, as some breeds appear to be overrepresented, although this is not well established. The presence of oral trauma or microabrasions, such as from chewing on hard objects or dental disease, provides a portal of entry for the virus. Poor oral hygiene and concurrent oral infections may also predispose to infection. In cats, immunosuppressive diseases such as feline immunodeficiency virus (FIV) or feline leukemia virus (FeLV) may increase susceptibility, although oral papillomatosis is rare in this species.

The clinical signs of oral papillomatosis are primarily related to the presence of multiple oral masses. The lesions are typically white to gray, cauliflower-like, pedunculated or sessile growths that can vary in size from a few millimeters to several centimeters. They are most commonly located on the lips, tongue, gingiva, palate, and pharynx. In the early stages, lesions may be small and smooth, but they rapidly enlarge and become hyperkeratotic. The number of lesions can range from a few to hundreds. Clinical signs may include halitosis, excessive drooling (ptyalism), difficulty eating (dysphagia), reluctance to chew, weight loss, and oral bleeding. If lesions are located in the pharynx or larynx, they can cause coughing, gagging, respiratory distress, and changes in voice. Secondary bacterial infection of ulcerated lesions can lead to pain, fever, and regional lymphadenopathy. In immunocompetent animals, the lesions typically regress spontaneously within 1 to 5 months, often without any treatment. During regression, the lesions may become inflamed, ulcerated, and then shrink. In immunocompromised animals, the lesions may persist, enlarge, and become more numerous. Malignant transformation to squamous cell carcinoma is rare but can occur, especially in older animals with chronic lesions. In such cases, the lesions may become invasive, ulcerated, and non-healing.

The differential diagnoses for oral papillomatosis include other oral masses and proliferative lesions. Key differentials include:

1. **Squamous cell carcinoma (SCC)**: A malignant neoplasm of the oral cavity, more common in older animals. SCC lesions are typically solitary, ulcerated, and invasive, with a broad base. Histopathology is definitive, showing invasive cords and nests of squamous epithelial cells with keratin pearls.

2. **Fibrosarcoma**: A malignant mesenchymal tumor that can occur in the oral cavity, often on the gingiva or hard palate. It is firm, locally invasive, and may be ulcerated. Histopathology shows spindle-shaped fibroblasts with a herringbone pattern.

3. **Epulis**: A benign, slow-growing mass of the gingiva, often arising from the periodontal ligament. There are several types (fibromatous, ossifying, acanthomatous). Acanthomatous epulis is locally invasive but benign. Histopathology is diagnostic.

4. **Oral melanoma**: A malignant neoplasm of melanocytes, common in dogs with pigmented oral mucosa. It appears as a darkly pigmented, ulcerated mass. Histopathology with immunohistochemistry (Melan-A, S100) is confirmatory.

5. **Infectious stomatitis**: Chronic inflammatory conditions, such as feline chronic gingivostomatitis, can cause proliferative lesions, but they are typically more diffuse and erythematous. Biopsy and response to treatment help differentiate.

6. **Eosinophilic granuloma complex (in cats)**: Can present as oral ulcers or proliferative lesions, but histopathology shows eosinophilic infiltrates.

7. **Foreign body granuloma**: A localized inflammatory response to a foreign body, such as a grass awn, can cause a mass. History and histopathology are helpful.

8. **Viral papillomas (other types)**: In dogs, cutaneous papillomas caused by other papillomavirus types may occur, but they are typically on the skin, not the oral mucosa.

9. **Oral eosinophilic granuloma (in dogs)**: Rare, but can cause oral masses. Histopathology shows eosinophilic infiltrates.

10. **Granular cell tumor**: A rare, benign neoplasm of the oral cavity, often on the tongue. Histopathology shows large cells with granular cytoplasm.

The diagnostic approach to oral papillomatosis is as follows:

1. **History and physical examination**: Obtain a thorough history, including age, vaccination status, exposure to other animals, and any signs of immunosuppression. Perform a complete oral examination, noting the number, size, location, and appearance of lesions. Palpate regional lymph nodes for enlargement.

2. **Clinical suspicion**: The presence of multiple, cauliflower-like, white to gray oral masses in a young dog is highly suggestive of oral papillomatosis.

3. **Cytology (optional)**: Fine-needle aspiration of a lesion may show keratinocytes with koilocytosis (perinuclear halos) and occasional intranuclear inclusion bodies, but cytology is not definitive.

4. **Biopsy and histopathology**: This is the gold standard for diagnosis. A biopsy of a representative lesion should be obtained, preferably a small, intact papilloma. Histopathology will show papillary hyperplasia of the stratified squamous epithelium with hyperkeratosis, koilocytosis, and intranuclear inclusion bodies in some cases. The basement membrane is intact, and there is no invasion.

5. **Molecular testing (PCR)**: Polymerase chain reaction (PCR) can detect papillomavirus DNA in tissue samples. This is useful for confirmation, especially in atypical cases. PCR can also be used to identify the specific viral type.

6. **Immunohistochemistry**: Detection of papillomavirus antigens using antibodies against L1 capsid protein can be performed on formalin-fixed tissue. This is less commonly used but can be confirmatory.

7. **Rule out other differentials**: If the lesions are atypical (e.g., solitary, ulcerated, or in an older animal), additional diagnostics such as imaging (CT or MRI) and biopsy are essential to rule out malignancy.

8. **Assessment of immune status**: If the animal is older or has recurrent/persistent lesions, consider evaluating for underlying immunosuppression (e.g., complete blood count, serum biochemistry, viral testing for FeLV/FIV in cats, or immune function tests).

In uncomplicated oral papillomatosis, routine laboratory findings are typically unremarkable. Complete blood count (CBC) may show mild leukocytosis if secondary bacterial infection is present. Serum biochemistry is usually normal. In immunocompromised animals, there may be lymphopenia or other abnormalities related to the underlying cause. If the animal has difficulty eating, there may be dehydration and electrolyte imbalances. Specific biomarkers are not typically evaluated. Serology for papillomavirus is not routinely available. PCR on tissue samples is the most sensitive and specific test for confirming the presence of viral DNA. In cases of suspected malignant transformation, histopathology is essential.

Imaging is not typically required for the diagnosis of oral papillomatosis, as the lesions are visible on oral examination. However, if the lesions extend into the pharynx or larynx, or if there is suspicion of malignancy, imaging may be indicated. Intraoral radiographs can assess for bone involvement in cases of suspected malignancy. Computed tomography (CT) or magnetic resonance imaging (MRI) may be used to evaluate the extent of deep tissue involvement, especially for surgical planning. On CT, papillomas appear as soft tissue masses arising from the oral mucosa, with no evidence of bone lysis unless malignant transformation has occurred. MRI may show hyperintense signal on T2-weighted images. Endoscopy can be used to visualize lesions in the caudal oral cavity and pharynx.

Cytology from fine-needle aspiration of a papilloma may show clusters of keratinocytes with variable degrees of keratinization, koilocytosis (perinuclear halos), and occasional anucleate squamous cells. Inflammatory cells may be present if there is secondary infection. However, cytology is not definitive and cannot differentiate papilloma from other epithelial neoplasms. Histopathology is the gold standard. On histopathological examination, oral papillomas are characterized by multiple papillary projections of hyperplastic stratified squamous epithelium supported by a fibrovascular core. The epithelium shows orthokeratotic or parakeratotic hyperkeratosis, acanthosis, and koilocytosis. Intranuclear inclusion bodies may be seen in some cases, particularly in the granular layer. The basement membrane is intact, and there is no invasion of the underlying connective tissue. In cases of malignant transformation, there will be evidence of invasion, cellular atypia, and loss of maturation.

In most cases, oral papillomatosis is self-limiting, and no specific treatment is required. Spontaneous regression typically occurs within 1 to 5 months. However, treatment may be indicated in cases where lesions are extensive, causing significant clinical signs (e.g., dysphagia, respiratory distress), or when they persist beyond 6 months. Treatment options include:

1. **Surgical excision**: Surgical removal of lesions may be performed, but it is important to note that incomplete excision may lead to recurrence, and surgery may not be necessary for small, non-obstructive lesions. Surgical trauma may also stimulate viral spread.

2. **Cryotherapy**: Cryosurgery using liquid nitrogen can be effective for individual lesions. It is less invasive than surgical excision and can be performed without general anesthesia in some cases.

3. **Laser ablation**: Carbon dioxide (CO2) laser ablation is a precise method for removing papillomas, with minimal bleeding and postoperative pain.

4. **Immunomodulatory therapy**: Azithromycin (10 mg/kg PO q24h for 10 days, then every other day for 30-60 days) has been reported to be effective in some cases, possibly due to its immunomodulatory and anti-inflammatory properties. Imiquimod 5% cream (applied topically to lesions 3 times per week) has also been used, but it is not approved for veterinary use and may cause local irritation.

5. **Autogenous vaccine**: An autogenous vaccine prepared from homogenized papilloma tissue has been used historically, but its efficacy is variable and it is not widely available.

6. **Supportive care**: If the animal has difficulty eating, provide soft food, ensure adequate hydration, and consider nutritional support. Antibiotics may be indicated for secondary bacterial infections.

7. **Management of underlying immunosuppression**: If the animal is immunosuppressed, address the underlying cause (e.g., discontinue immunosuppressive drugs, treat concurrent infections).

The prognosis for oral papillomatosis is excellent in immunocompetent animals. Spontaneous regression occurs in the vast majority of cases within 1 to 5 months, and recurrence is rare. In immunocompromised animals, the disease may persist, but with appropriate management of the underlying cause, regression can still occur. Malignant transformation is rare, but if it occurs, the prognosis is guarded and depends on the stage and treatment. Overall, the mortality rate is very low, and most animals recover fully without long-term sequelae.

Follow-up is typically not required for uncomplicated cases, as the lesions regress spontaneously. However, if treatment is instituted, re-evaluation should be performed every 2 to 4 weeks to monitor response. For persistent or recurrent lesions, a biopsy should be repeated to rule out malignancy. In animals with underlying immunosuppression, regular monitoring of immune status and the lesions is recommended. If surgical excision or laser ablation is performed, the surgical site should be monitored for healing and recurrence. Long-term follow-up is not necessary for animals that have fully recovered.

**Pearls:** - Oral papillomatosis is most common in young dogs (<2 years) and is usually self-limiting. - The characteristic cauliflower-like appearance is often diagnostic. - Spontaneous regression is the rule; avoid aggressive treatment unless lesions are obstructive or persistent. - Azithromycin may be a useful adjunctive therapy, but its efficacy is not well established. - Always consider immunosuppression in adult animals with persistent or recurrent papillomatosis.

**Pitfalls:** - Do not confuse oral papillomatosis with squamous cell carcinoma, especially in older animals. Biopsy is essential for atypical lesions. - Avoid surgical excision in the early stages, as it may stimulate viral spread and recurrence. - Do not use immunosuppressive drugs (e.g., corticosteroids) in animals with papillomatosis, as they can worsen the disease. - Be aware that papillomas can be transmitted to other animals, so isolate affected animals from susceptible ones. - Do not attempt to treat with topical caustic agents, as they can cause tissue damage and secondary infection.

Based on Plumb's Veterinary Drug Handbook, the following drug protocols may be considered for oral papillomatosis:

1. **Azithromycin**: 10 mg/kg PO q24h for 10 days, then 10 mg/kg PO q48h for 30-60 days. This macrolide antibiotic has immunomodulatory properties and has been reported to induce regression of papillomas in some dogs. It is generally well tolerated, with gastrointestinal upset as the most common adverse effect. Use with caution in animals with hepatic disease.

2. **Imiquimod 5% cream**: Apply topically to each lesion 3 times per week. This is an immune response modifier that induces local cytokine production. It is not approved for veterinary use, and safety and efficacy are not well established. It may cause local erythema, ulceration, and pain. Do not use on mucous membranes unless directed by a specialist.

3. **Antibiotics for secondary infection**: If secondary bacterial infection is present, choose an appropriate antibiotic based on culture and sensitivity. Common choices include amoxicillin-clavulanate (13.75 mg/kg PO q12h) or clindamycin (5.5-11 mg/kg PO q12h).

4. **Analgesics**: If the animal has oral pain, consider nonsteroidal anti-inflammatory drugs (NSAIDs) such as carprofen (2.2 mg/kg PO q12h) or meloxicam (0.1 mg/kg PO q24h). Use with caution in animals with renal or hepatic disease.

5. **Immunosuppressive drugs**: These are contraindicated in papillomatosis, as they can exacerbate the disease.

Note: Always consult the latest edition of Plumb's Veterinary Drug Handbook for current dosing and safety information.

The literature on oral papillomatosis is limited, but several key studies and reviews provide evidence for diagnosis and management. A study by Nicholls et al. (2001) demonstrated that regression of canine oral papillomas is associated with a T-helper 1 (Th1) immune response, with infiltration of CD4+ and CD8+ T cells. This supports the concept that cell-mediated immunity is crucial for viral clearance. A case series by Lange and Favrot (2011) reported successful treatment of canine papillomatosis with azithromycin, with complete regression in 80% of cases within 2 months. However, a more recent randomized controlled trial by Munday et al. (2015) found no significant difference between azithromycin and placebo, suggesting that spontaneous regression may account for the observed improvement. A review by Munday (2014) highlighted the potential for malignant transformation of papillomas, particularly in immunosuppressed animals, and recommended biopsy for persistent lesions. The ACVIM consensus statement on the diagnosis and treatment of canine oral tumors (2016) includes papillomatosis in the differential diagnosis and recommends histopathology for definitive diagnosis. Overall, the evidence supports a conservative approach, with treatment reserved for cases with significant clinical signs or persistence beyond 6 months. Immunomodulatory therapies show promise but require further investigation.